CME online

in association with the 6th Heart in Diabetes (HiD)

Diabetes Kidney Disease Closing the Loop in CardioRenal Protections

This is a CME Symposium Supported by an Educational Grant from Bayer
Provided By:

Administrated by:
This CME online educational activity is approved for a maximum of 1.75 AMA PRA Category 1 Credits ™.
Accreditation period: August 1, 2022 – August 1, 2023

To get started:

Login / Register
CME information
View Agenda
Course presentation

To Receive a Certificate for This CME Activity:  

View the presentations in this CME activity and complete the evaluation. Your certificate will be mailed to you upon satisfactory completion of these documents.

The Primary Prevention of CHF and CKD in Diabetes
Agenda

Introduction & Pre-CME Questions
Matthew R. Weir, MD

Diabetes, Kidney and Heart Disease- Overview
Matthew R. Weir, MD

Pathogenesis of CKD in Diabetes
Susanne B. Nicholas, MD

Management Diabetic Kidney Disease- Circa 2022
Peter Rossing, MD, DMSc

Panel Discussion and Q&A - Closing the Loop- the Management of CKD in DM
Panel: Peter Rossing, MD • DMSc • Matthew R. Weir, MD • Yehuda Handelsman, MD
Moderator: Mikhail Kosiborod, MD

Faculty

Mikhail N. Kosiborod MD, FACC, FAHA

Professor of Medicine Saint Luke's Mid America Heart Institute University of Missouri-Kansas City School of Medicine
Kansas City, Missouri

Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE

Medical Director & Principal Investigator
The Metabolic Institute of America
Chair & Program Director
World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) / Heart in Diabetes (HID)
Chair & Founder
International Committee for Insulin Resistance
Tarzana, California

Matthew R. Weir, MD

Professor and Chief
Division of Nephrology
Department of Medicine
University of Maryland School of Medicine
Baltimore, Maryland

Susanne B. Nicholas, M.D., M.P.H., Ph.D., FASN

Professor of Medicine
Director, Laboratory for Chronic Kidney Disease
Pathogenic Mechanisms And Therapeutics
Divisions of Nephrology and Endocrinology
David Geffen School of Medicine at UCLA
Los Angeles, California

Peter Rossing, DMSc, MD

Research leader, professor
Complications Research
Copenhagen, Denmark

Program Description

Diabetic kidney disease (DKD), type 2 diabetes (T2D) cardiovascular disease (CVD), and heart failure (HF) share a common etiology involving hyperglycemia, hypertension, inflammation, fibrosis, oxidative stress, and increased renin-angiotensinaldosterone system (RAAS) activity. Both CKD and T2D are common, affecting 14% and 11% of the US population, respectively. 36% of patients with diabetes also have DKD, which is the leading cause of end-stage renal disease (ESRD) and more than doubles their risk of cardiovascular events and triples the risk of heart failure (HF). Traditional approach to management of CKD has been based on blocking RAAS with ACE and ARB inhibitors. Yet, achieving optimal outcomes from treating DKD and T2D remains a challenge. Identifying patients with eGFR and spot urinary albumin-creatinine ratio is valuable and would support early intervention. Recently sodium glucose cotransporter 2 (SGLT2) inhibitors were added to the management of these patients. Diabetes kidney disease progression is also driven by inflammation and fibrosis underscoring the need for newer medications. A new class the nonsteroidal MRAs specifically finerenone has shown significant clinical benefits with reduced side effect profile as seen by the recent CVOTs FIDELIO and FIGARO. In these studies, finerenone improved CKD and heart disease in patients with DKD. In this CME symposium we will explore these issues addressing the pathophysiology of DKD and the contemporary role of its management with focus on the role of the new class of non-steroidal MRA CKD, CVD and HF outcome.


Learning Objectives

Upon completion of this CME symposium, participants should be able to:

  • Describe the etiologic and pathophysiologic links between DKD, T2D, HF, and CVD and the disease burden of CKD and associated cardiometabolic conditions
  • Compare and contrast the benefits and limitations of treatments indicated for CKD management, including RAAS blockade agents, first generation MRAs, and SGLT2 inhibitors
  • Discuss the evidence for the efficacy, safety, and clinical outcomes of FIDELIO and FIGARO
  • Evaluate the role nonsteroidal MRAs play in optimizing cardiorenal outcomes in the management of chronic kidney disease (CKD) in patients with type 2 diabetes (T2D)
  • Design optimal therapeutic regimens for the prevention and management of CKD progression and complications in patients with CKD

    • Target Audience

    This educational initiative is designed for cardiologists, nephrologists, endocrinologists, primary care physicians, internists, and other healthcare professionals interested in the Epidemiology, pathophysiology, prevention, and treatment of diabetes with CKD and prevention of related morbidity and mortality.

    CME Statement

    This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PESI Inc., and Metabolic Endocrine Education Foundation (MEEF). PESI Inc., is accredited by the ACCME to provide continuing medical education for physicians.

    PESI, Inc, designated this live educational activity for a maximum of 1.75 AMA PRA Category 1 Credit(s).

    For information please contact: [email protected] or 818 342 1889

    This is a CME Program Supported by an Educational Grant from Bayer